Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | FR alpha peptide vaccine |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
FR alpha peptide vaccine | Multi-epitope Folate Receptor Alpha Peptide Vaccine | FR alpha peptide vaccine is a peptide vaccine comprised of multi-epitopes of the folate receptor alpha, which may induce cytotoxic immune response against FR alpha-expressing tumors (PMID: 29545464). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | Her2-receptor negative breast cancer | not applicable | FR alpha peptide vaccine | Phase I | Actionable | In a Phase I trial, FR alpha peptide vaccine demonstrated safety, induced durable immune response against Folr1 in hormone receptor-positive, ERBB2 (HER2)-negative breast cancer patients who completed standard treatment, and all patients (n=8) remained alive 2 years after initial immunization, with a median relapse-free survival not reached; however, T cell response did not correlate with tumor Folr1 expression level (PMID: 29545464; NCT01606241). | 29545464 |
Unknown unknown | ovarian cancer | not applicable | FR alpha peptide vaccine | Phase I | Actionable | In a Phase I trial, FR alpha peptide vaccine demonstrated safety, induced durable immune response against Folr1 in ovarian cancer patients who completed standard treatment, and all patients (n=14) remained alive 2 years after initial immunization, with a median relapse-free survival of 528 days; however, T cell response did not correlate with tumor Folr1 expression level (PMID: 29545464; NCT01606241). | 29545464 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|